Sunovion submits NDA for dasotraline to US FDA to treat ADHD patients
Sunovion Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for dasotraline to treat patients with attention deficit hyperactivity disorder (ADHD).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: ADHD | Food and Drug Administration (FDA) | Hyperactivity | New Drug Applications | Pharmaceuticals